San Ali, Rahman Raphia K, Sanmugananthan Praveen, Dubé Michael D, Panico Nicholas, Ariwodo Ogechukwu, Shah Vidur, D'Amico Randy S
College of Osteopathic Medicine, Kansas City University, Kansas City, MO 64106, USA.
Department of Neurological Surgery, Riverside University Health System, Moreno Valley, CA 92501, USA.
Cancers (Basel). 2023 Sep 22;15(19):4680. doi: 10.3390/cancers15194680.
Patients with meningiomas may have reduced health-related quality of life (HRQoL) due to postoperative neurological deficits, cognitive dysfunction, and psychosocial burden. Although advances in surgery and radiotherapy have improved progression-free survival rates, there is limited evidence regarding treatment outcomes on HRQoL. This review examines HRQoL outcomes based on tumor location and treatment modality. A systematic search in PubMed yielded 28 studies with 3167 patients. The mean age was 54.27 years and most patients were female (70.8%). Approximately 78% of meningiomas were located in the skull base (10.8% anterior, 23.3% middle, and 39.7% posterior fossae). Treatment modalities included craniotomy (73.6%), radiotherapy (11.4%), and endoscopic endonasal approach (EEA) (4.0%). The Karnofsky Performance Scale (KPS) was the most commonly utilized HRQoL instrument (27%). Preoperative KPS scores > 80 were associated with increased occurrence of postoperative neurological deficits. A significant difference was found between pre- and post-operative KPS scores for anterior/middle skull base meningiomas (SBMs) in comparison to posterior (SBMs) when treated with craniotomy. Post-craniotomy SF-36 scores were lower for posterior SBMs in comparison to those in the anterior and middle fossae. Risk factors for poor neurological outcomes include a high preoperative KPS score and patients with posterior SBMs may experience a greater burden in HRQoL.
由于术后神经功能缺损、认知功能障碍和心理社会负担,脑膜瘤患者的健康相关生活质量(HRQoL)可能会降低。尽管手术和放疗技术的进步提高了无进展生存率,但关于HRQoL治疗结果的证据有限。本综述基于肿瘤位置和治疗方式研究了HRQoL结果。在PubMed上进行的系统检索得到了28项研究,共3167例患者。平均年龄为54.27岁,大多数患者为女性(70.8%)。约78%的脑膜瘤位于颅底(前颅底10.8%、中颅底23.3%、后颅底39.7%)。治疗方式包括开颅手术(73.6%)、放疗(11.4%)和鼻内镜下经鼻入路(EEA)(4.0%)。卡氏功能状态评分(KPS)是最常用的HRQoL评估工具(27%)。术前KPS评分>80与术后神经功能缺损发生率增加相关。开颅手术治疗时,前/中颅底脑膜瘤(SBMs)术前和术后KPS评分与后颅底脑膜瘤相比存在显著差异。与前颅窝和中颅窝脑膜瘤相比,后颅底脑膜瘤开颅术后SF-36评分更低。神经功能预后不良的危险因素包括术前KPS评分高,后颅底脑膜瘤患者的HRQoL负担可能更大。